Precautions that cannot be ignored when using pralatrexate injection

During treatment with Pralatrexate Injection, patients must closely adhere to the following precautions to ensure the safety and effectiveness of the drug:

Monitor hematological indicators: Pralatrexate can cause bone marrow suppression. Therefore, patients need to undergo regular hematological tests during treatment, including white blood cell count, red blood cell count, platelet count, etc. This helps to detect and treat hematological abnormalities promptly and avoid severe anemia, infection or bleeding.

Liver function monitoring: Since pralatrexate may cause liver function damage, patients must regularly check liver enzyme levels when using this drug and pay close attention to whether there are symptoms of liver damage such as jaundice and loss of appetite. If liver function abnormalities occur, the drug dosage should be adjusted or discontinued according to the doctor's recommendations.

Avoid combination with other hepatotoxic drugs: When using pralatrexate, avoid combination with other drugs known to be hepatotoxic to reduce the burden on the liver. If the patient is taking other medications, the doctor must be informed so that drug-drug interactions can be evaluated.

Pulmonary function assessment: Pralatrexate has potential pulmonary toxicity; therefore, pulmonary function assessment should be performed periodically during treatment. If patients develop symptoms such as shortness of breath, cough, or chest pain, they should seek medical attention immediately for early treatment.

Prevention of infection: The immunosuppressive effect of pralatrexate may lead to an increased risk of infection. Patients should pay special attention to avoid contact with sources of infection and take necessary protective measures. If fever or other symptoms of infection occur, seek medical attention promptly and consider using anti-infective drugs.

Contraceptive measures: Pralatrexate may cause fetal harm, therefore, both men and women should use effective contraceptive methods during treatment. If the patient is planning to become pregnant or is breastfeeding, she should discuss it with her doctor before treatment to avoid adverse effects on the fetus or baby.

Weight and nutritional management during treatment: Because pralatrexate may cause gastrointestinal discomfort, patients may experience loss of appetite or weight loss. Ensure that the patient takes in adequate nutrition during treatment, and if necessary, nutritional supplements can be provided under the guidance of a doctor.

Reference materials:https://www.drugs.com/pro/pralatrexate-injection.html